Eli Lilly Scores Major Win in Weight-Loss Drug Race
Moz Farooque ACCA
Wed, August 12, 2026 at 12:37 AM GMT+5:30
2 min read
- LLY
-1.40% - NVO
-1.17%
This article first appeared on GuruFocus
Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly’s opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry’s fastest-growing markets
Is LLY fairly valued? Test your thesis with our free DCF calculator
Lilly is one of the world’s largest pharmaceutical companies, with diabetes and obesity treatments driving an increasing share of growth. Its portfolio includes injectable Mounjaro and Zepbound, while Foundayo, also known as orforglipron, extends its GLP-1 franchise into pills
Britain’s Medicines and Healthcare products Regulatory Agency authorized Foundayo on Aug. 10 for weight management and Type 2 diabetes. The pill can be taken once daily at any time without food or water restrictions, potentially offering a convenience advantage for patients
The U.K. approval follows Foundayo’s U.S. clearance on April 1. It also intensifies competition with Novo Nordisk, whose oral Wegovy received U.K. approval in June
Foundayo is still early in its commercial ramp, generating $98 million in second-quarter sales. But Lilly’s broader obesity franchise is already powering extraordinary growth: companywide Q2 revenue jumped 48% to $23 billion, driven primarily by Mounjaro and Zepbound volume
Investor Takeaway
The next question is how quickly Foundayo can translate regulatory approvals into meaningful sales
For investors, U.K. reimbursement will be critical. Although Foundayo is now approved, the MHRA says it is not currently available through the National Health Service, with NICE still needing to evaluate the treatment before broader NHS access
That makes reimbursement decisions, prescription growth and additional international approvals the key catalysts
If Foundayo gains traction alongside Zepbound rather than merely cannibalizing injections, Lilly could broaden the addressable GLP-1 population substantially. But slower uptake versus Novo Nordisk’s competing pill, pricing pressure or limited reimbursement could temper the opportunity despite the regulatory momentum
